Procept BioRobotics [PRCT] vs Boston Scientific [BSX] Detailed Stock Comparison

Procept BioRobotics
NASDAQ
Loading...

Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Procept BioRobotics wins in 4 metrics, Boston Scientific wins in 14 metrics, with 0 ties. Boston Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Procept BioRobotics | Boston Scientific | Better |
---|---|---|---|
P/E Ratio (TTM) | -27.50 | 61.28 | Procept BioRobotics |
Price-to-Book Ratio | 6.84 | 6.80 | Boston Scientific |
Debt-to-Equity Ratio | 21.02 | 53.09 | Procept BioRobotics |
PEG Ratio | -36.18 | 36.90 | Procept BioRobotics |
EV/EBITDA | -26.72 | 35.51 | Procept BioRobotics |
Profit Margin (TTM) | -36.20% | 13.55% | Boston Scientific |
Operating Margin (TTM) | -39.67% | 18.63% | Boston Scientific |
EBITDA Margin (TTM) | N/A | 18.63% | N/A |
Return on Equity | -27.62% | 11.55% | Boston Scientific |
Return on Assets (TTM) | -13.36% | 5.39% | Boston Scientific |
Free Cash Flow (TTM) | $-103.62M | $2.37B | Boston Scientific |
Dividend Yield | 0.64% | N/A | N/A |
1-Year Return | -25.26% | 35.14% | Boston Scientific |
Price-to-Sales Ratio (TTM) | 10.69 | 8.25 | Boston Scientific |
Enterprise Value | $2.43B | $167.06B | Boston Scientific |
EV/Revenue Ratio | 9.75 | 9.03 | Boston Scientific |
Gross Profit Margin (TTM) | 63.85% | 67.65% | Boston Scientific |
Revenue per Share (TTM) | $5 | $13 | Boston Scientific |
Earnings per Share (Diluted) | $-1.69 | $1.68 | Boston Scientific |
Beta (Stock Volatility) | 1.04 | 0.66 | Boston Scientific |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Procept BioRobotics vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Procept BioRobotics | -3.07% | -18.39% | -30.51% | -25.46% | -43.09% | -52.39% |
Boston Scientific | 0.19% | -1.87% | -0.84% | -1.76% | -2.18% | 15.19% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Procept BioRobotics | -25.26% | 4.46% | 14.23% | 14.23% | 14.23% | 14.23% |
Boston Scientific | 35.14% | 143.23% | 162.92% | 490.71% | 1,778.83% | 263.69% |
Performance & Financial Health Analysis: Procept BioRobotics vs Boston Scientific
Metric | PRCT | BSX |
---|---|---|
Market Information | ||
Market Cap | $2.66B | $152.55B |
Market Cap Category | Mid cap | Large cap |
10 Day Avg. Volume | 1,476,630 | 6,789,663 |
90 Day Avg. Volume | 1,040,502 | 7,511,608 |
Last Close | $38.38 | $103.15 |
52 Week Range | $37.12 - $103.81 | $74.01 - $108.94 |
% from 52W High | -63.03% | -5.31% |
All-Time High | $103.81 (Nov 11, 2024) | $108.94 (Jul 23, 2025) |
% from All-Time High | -63.03% | -5.31% |
Growth Metrics | ||
Quarterly Revenue Growth | 0.55% | 0.23% |
Quarterly Earnings Growth | 0.55% | 1.46% |
Financial Health | ||
Profit Margin (TTM) | -0.36% | 0.14% |
Operating Margin (TTM) | -0.40% | 0.19% |
Return on Equity (TTM) | -0.28% | 0.12% |
Debt to Equity (MRQ) | 21.02 | 53.09 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | $7.04 | $15.14 |
Cash per Share (MRQ) | $5.72 | $0.36 |
Operating Cash Flow (TTM) | $-83,907,000 | $4.28B |
Levered Free Cash Flow (TTM) | $-58,771,876 | $2.94B |
Dividends | ||
Last 12-Month Dividend Yield | 0.64% | N/A |
Last 12-Month Dividend | $0.38 | N/A |
Valuation & Enterprise Metrics Analysis: Procept BioRobotics vs Boston Scientific
Metric | PRCT | BSX |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | -27.50 | 61.28 |
Forward P/E | -36.18 | 36.90 |
PEG Ratio | -36.18 | 36.90 |
Price to Sales (TTM) | 10.69 | 8.25 |
Price to Book (MRQ) | 6.84 | 6.80 |
Market Capitalization | ||
Market Capitalization | $2.66B | $152.55B |
Enterprise Value | $2.43B | $167.06B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 9.75 | 9.03 |
Enterprise to EBITDA | -26.72 | 35.51 |
Risk & Other Metrics | ||
Beta | 1.04 | 0.66 |
Book Value per Share (MRQ) | $7.04 | $15.14 |
Financial Statements Comparison: Procept BioRobotics vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | PRCT | BSX |
---|---|---|
Revenue/Sales | $69.16M | $4.66B |
Cost of Goods Sold | $25.00M | $1.45B |
Gross Profit | $44.16M | $3.21B |
Research & Development | $16.40M | $443.00M |
Operating Income (EBIT) | $-27.44M | $937.00M |
EBITDA | $-22.39M | $1.23B |
Pre-Tax Income | $-24.74M | $805.00M |
Income Tax | N/A | $133.00M |
Net Income (Profit) | $-24.74M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | PRCT | BSX |
---|---|---|
Cash & Equivalents | $316.21M | $725.00M |
Total Current Assets | $465.79M | $7.34B |
Total Current Liabilities | $52.06M | $5.06B |
Long-Term Debt | $77.83M | $10.93B |
Total Shareholders Equity | $389.16M | $22.45B |
Retained Earnings | $-570.72M | $3.35B |
Property, Plant & Equipment | $21.26M | $448.00M |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | PRCT | BSX |
---|---|---|
Operating Cash Flow | $-11.65M | $513.00M |
Capital Expenditures | $-1.84M | $-187.00M |
Free Cash Flow | $-18.82M | $277.00M |
Debt Repayment | N/A | $-1.31B |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | PRCT | BSX |
---|---|---|
Shares Short | 6.82M | 19.57M |
Short Ratio | 9.53 | 2.65 |
Short % of Float | 0.15% | 0.01% |
Average Daily Volume (10 Day) | 1,476,630 | 6,789,663 |
Average Daily Volume (90 Day) | 1,040,502 | 7,511,608 |
Shares Outstanding | 54.72M | 1.47B |
Float Shares | 53.21M | 1.48B |
% Held by Insiders | 0.04% | 0.00% |
% Held by Institutions | 0.94% | 0.94% |
Dividend Analysis & Yield Comparison: Procept BioRobotics vs Boston Scientific
Metric | PRCT | BSX |
---|---|---|
Last 12-Month Dividend | $0.38 | N/A |
Last 12-Month Dividend Yield | 0.64% | N/A |
3-Year Avg Annual Dividend | $0.53 | N/A |
3-Year Avg Dividend Yield | 0.12% | N/A |
3-Year Total Dividends | $1.59 | N/A |
Ex-Dividend Date | Mar 31, 2025 | N/A |